Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
Share Market News
ASX 200 jumps 1.3%: Big four banks drop lower, Afterpay up after U.S. update
Share Market News
Here are the 10 most shorted shares on the ASX
Share Market News
These are 10 most shorted shares on the ASX
How to invest
How to turn $20,000 into over $200,000 in 10 years with ASX shares
Share Market News
Here are the 10 most shorted shares on the ASX
Share Market News
These 5 ASX shares were last week's top performers
⏸️ TMF AMP
ASX 200 Weekly Wrap: ASX back in the green
Share Market News
These are the 10 most shorted ASX shares
Share Gainers
These were the best performers on the ASX 200 last week
Share Market News
ASX 200 finishes higher by 0.8%, Carsales share price driven up by FY20 guidance
Share Market News
Clinuvel share price jumps as investors favour healthcare
Share Market News
These are the 10 most shorted ASX shares
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
